Moomoo AI 已提取核心訊息
Eli Lilly and Company (NYSE: LLY), a global pharmaceutical company, reported a strong financial performance for the fourth quarter of 2023, with a 28% increase in revenue compared to the same period in 2022. The company's revenue for Q4 2023 was $9.35 billion, driven by higher realized prices and volume growth. New Products revenue, led by Mounjaro and Zepbound, grew to $2.49 billion, while Growth Products revenue, led by Verzenio and Jardiance, increased by 9% to $5.27 billion. The company's EPS also saw a significant increase, with reported EPS growing 13% to $2.42 and non-GAAP EPS increasing 19% to $2.49. Eli Lilly provided guidance for 2024, projecting revenue in the range of $40.4 billion to $41.6 billion and EPS between $11.80 and $12.30 on a reported basis, and $12.20 to $12.70 on a non-GAAP basis. The...Show More
Eli Lilly and Company (NYSE: LLY), a global pharmaceutical company, reported a strong financial performance for the fourth quarter of 2023, with a 28% increase in revenue compared to the same period in 2022. The company's revenue for Q4 2023 was $9.35 billion, driven by higher realized prices and volume growth. New Products revenue, led by Mounjaro and Zepbound, grew to $2.49 billion, while Growth Products revenue, led by Verzenio and Jardiance, increased by 9% to $5.27 billion. The company's EPS also saw a significant increase, with reported EPS growing 13% to $2.42 and non-GAAP EPS increasing 19% to $2.49. Eli Lilly provided guidance for 2024, projecting revenue in the range of $40.4 billion to $41.6 billion and EPS between $11.80 and $12.30 on a reported basis, and $12.20 to $12.70 on a non-GAAP basis. The company's financial results were bolstered by FDA approvals of Zepbound for obesity and Jaypirca for chronic lymphocytic leukemia, as well as positive results from a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH). Additionally, Eli Lilly completed acquisitions of POINT Biopharma Global Inc. and Mablink Biosciences SAS, and announced a 15% annual increase in its quarterly dividend.
全球製藥公司禮來公司（紐約證券交易所代碼：LLY）報告了2023年第四季度的強勁財務表現，收入與2022年同期相比增長了28％。該公司2023年第四季度的收入爲93.5億美元，這得益於更高的已實現價格和銷量增長。以Mounjaro和Zepbound爲首的新產品收入增長至24.9億美元，而以Verzenio和Jardiance爲首的成長產品收入增長了9％，達到52.7億美元。該公司的每股收益也大幅增長，報告的每股收益增長13％，至2.42美元，非公認會計准則每股收益增長19％，至2.49美元。禮來公司提供了2024年的指導方針，預計收入在404億美元至416億美元之間，按報告計算，每股收益在11...展開全部
全球製藥公司禮來公司（紐約證券交易所代碼：LLY）報告了2023年第四季度的強勁財務表現，收入與2022年同期相比增長了28％。該公司2023年第四季度的收入爲93.5億美元，這得益於更高的已實現價格和銷量增長。以Mounjaro和Zepbound爲首的新產品收入增長至24.9億美元，而以Verzenio和Jardiance爲首的成長產品收入增長了9％，達到52.7億美元。該公司的每股收益也大幅增長，報告的每股收益增長13％，至2.42美元，非公認會計准則每股收益增長19％，至2.49美元。禮來公司提供了2024年的指導方針，預計收入在404億美元至416億美元之間，按報告計算，每股收益在11.80美元至12.30美元之間，按非公認會計准則計算，收入在12.20美元至12.70美元之間。該公司的財務業績得益於美國食品藥品管理局批准Zepbound用於肥胖症和Jaypirca用於治療慢性淋巴細胞白血病，以及一項針對非酒精性脂肪肝炎（NASH）成人替塞帕肽的2期研究的積極結果。此外，禮來公司完成了對POINT Biopharma Global Inc.和Mablink Biosciences SAS的收購，並宣佈其季度股息每年增長15％。
有用
沒用